Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca’s BYDUREON BCise Approves in the Us for the Treatment of Type 2 Diabetes

07/23/2021 | 07:00am EDT

AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. The approval by the US Food and Drug Administration (FDA) is the first regulatory approval for a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in this population, supported by the positive results of the BCB114 Phase III trial in youth with T2D between 10 and


© S&P Capital IQ 2021
All news about ASTRAZENECA PLC
11:06aASTRAZENECA : Vaccination Against Covid-19 Resumes Sept 24
AQ
10:18aVC DAILY : Biotechs Seek New Skill Set From -2-
DJ
10:06aRedhill Biopharma, AstraZeneca, Nektar Therapeutics Settle Movantik Patent Litigation w..
MT
10:00aWALL STREET STOCK EXCHANGE : As smooth as silk
08:05aASTRAZENECA : A Sense of Comfort, Providing Housing to Patients and their Families During ..
AQ
07:12aASTRAZENECA : Science Committee appointment (Form 6-K)
PU
06:52aASTRAZENECA : establishes new Sustainability Committee of the Board (Form 6-K)
PU
06:29aANALYST RECOMMENDATIONS : Amgen, Apple, AstraZeneca, FedEx, T-Mobile US...
06:06aASTRAZENECA : Coronavirus - 40,000 Vaccines Administered in Private Pharmacies
AQ
05:41aASTRAZENECA : Covid to be like the common cold - one day, says vaccine co-designer
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 33,3x
Yield 2021 2,37%
Capitalization 184 B 184 B -
EV / Sales 2021 5,89x
EV / Sales 2022 4,78x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 118,94 $
Average target price 136,23 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.35%182 344
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972